We are happy to report that 400 consented participants have been recruited to the AMYPAD Prognostic and Natural History Study (PNHS). The past months have seen good progress in the PNHS, with the activation of new sites, the inclusion of non-EPAD cohorts and the increased recruitment rate. To date, there are eigh sites actively recruiting participants into the PNHS in Amsterdam, Edinburgh, Toulouse, Barcelona, Geneva, Tayside, Montpellier and Paris. 641 subjects have been informed of which 400 consented. A total of 316 participants have been scanned so far. The AMYPAD PNHS is a longitudinal study looking at the progression to Alzheimer’s disease (AD) in individuals without dementia and with the help of amyloid positron emission tomography (PET) we will evaluate how amyloid imaging assists in improving the understanding of the natural course of this disease.
That means that the AMYPAD project has passed the mark of 1,000 research participants. Over 600 of the expected 900 patients have already been recruited at eight sites across Europe for the AMYPAD Diagnostic and Patient Management Study (DPMS). The DPMS is fully activated in Geneva, Amsterdam, Toulouse, Barcelona, London, Stockholm, Cologne and Lausanne, with a total of 653 patients and almost 450 amyloid PET scans performed. The AMYPAD DPMS has the primary objective to evaluate the impact of amyloid PET imaging on diagnostic thinking in a realistic population of possible AD dementia, Mild Cognitive Impairment (MCI), and Subjective Cognitive Decline PLUS (SCD) patients.
We are proud to have reached a new milestone! The AMYPAD team is confident that research participants will continue coming on board and that the AMYPAD research initiative will reach its objectives by the end of the project.